A Phase 1 interventional study of fimasartan in Renal Impairment, sponsored by Boryung Pharmaceutical Co., Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-01-09.
Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 1 and Interventional
The purpose of this study is to compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in renal impairment patients and healthy volunteers.
1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.
This study's enrollment of 16 is below the median of 43 across 1,504 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →Boryung Pharmaceutical Co., Ltd is the lead sponsor of 139 studies on the registry; 23 are open to participants now.
Counted across the registry records on this site, refreshed daily.
\<Renal impairment patient>
\<Healthy volunteer>
Exclusion Criteria:
renal impairment patients who eGFR is lower than 30 ml/min/1.73m\^2 without hemodialysis
Drug: fimasartan
healthy volunteers group
Drug: fimasartan
single administration of fimasartan 120mg
pharmacokinetic characteristic of fimasartan
AUC, Cmax, Tmax, T1/2, and CL/F of fimasartan
Time frame: 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 32, 48h
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boryung Pharmaceutical Co., Ltd